Rapport Therapeutics advances RAP-219 Phase 3 epilepsy program in Q2 2026

Rapport Therapeutics reported second quarter 2026 results on August 5, 2026, highlighting progress on its lead candidate RAP-219. The company initiated its Phase 3 program in focal onset seizures during the second quarter of 2026, with two parallel trials, FOCUS 1 and FOCUS 2, now enrolling patients.¹

China's National Medical Products Administration approved an Investigational New Drug application for RAP-219 Phase 3 trials in focal onset seizures, and Tenacia expects patient recruitment in China to begin in the fourth quarter of 2026.¹ Separately, most patients from the RAP-219 Phase 2 trial in focal onset seizures have enrolled in an open-label long-term safety trial, with initial data expected in the fourth quarter of 2026.¹

In April 2026, the company presented additional follow-up data from its Phase 2a trial. Therapeutic levels of RAP-219 were sustained during an 8-week follow-up period, with continued biomarker and clinical responses; long episodes fell by a median of 80% and clinical seizures by a median of 90% versus baseline in weeks 9-12, and by 68% and 59% respectively in weeks 13-16.¹ The company also raised its estimate of RAP-219's half-life to 22 days, up from a prior 14-day estimate, based on additional pharmacokinetic data and population modeling.¹

On other programs, Rapport continues preparing to start a Phase 3 trial of RAP-219 in primary generalized tonic-clonic seizures in the first half of 2027.¹ The Phase 2 bipolar mania trial remains on track for topline results in October 2026.¹ Work toward IND-enabling milestones for a long-acting injectable version of RAP-219 continues, with initial Phase 1 pharmacokinetic results expected in 2027.¹

On financials, the company held $436.1 million in cash, cash equivalents and short-term investments as of June 30, 2026, down from $476.8 million at the end of the first quarter, and said this is expected to fund operations into the second half of 2029.¹